首页> 外文期刊>European Journal of Medicinal Chemistry: Chimie Therapeutique >2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.
【24h】

2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.

机译:2D MI-DRAGON:蛋白质-配体相互作用的新预测因子和美国FDA药物靶标网络,MAO-A的氧代异阿波芬抑制剂和人类寄生虫蛋白的理论实验研究。

获取原文
获取原文并翻译 | 示例
           

摘要

There are many pairs of possible Drug-Proteins Interactions that may take place or not (DPIsDPIs) between drugs with high affinityon-affinity for different proteins. This fact makes expensive in terms of time and resources, for instance, the determination of all possible ligands-protein interactions for a single drug. In this sense, we can use Quantitative Structure-Activity Relationships (QSAR) models to carry out rational DPIs prediction. Unfortunately, almost all QSAR models predict activity against only one target. To solve this problem we can develop multi-target QSAR (mt-QSAR) models. In this work, we introduce the technique 2D MI-DRAGON a new predictor for DPIs based on two different well-known software. We use the software MARCH-INSIDE (MI) to calculate 3D structural parameters for targets and the software DRAGON was used to calculated 2D molecular descriptors all drugs showing known DPIs present in the Drug Bank (US FDA benchmark dataset). Both classes of parameters were used as input of different Artificial Neural Network (ANN) algorithms to seek an accurate non-linear mt-QSAR predictor. The best ANN model found is a Multi-Layer Perceptron (MLP) with profile MLP 21:21-31-1:1. This MLP classifies correctly 303 out of 339 DPIs (Sensitivity = 89.38%) and 480 out of 510 nDPIs (Specificity = 94.12%), corresponding to training Accuracy = 92.23%. The validation of the model was carried out by means of external predicting series with Sensitivity = 92.18% (625/678 DPIs; Specificity = 90.12% (730/780 nDPIs) and Accuracy = 91.06%. 2D MI-DRAGON offers a good opportunity for fast-track calculation of all possible DPIs of one drug enabling us to re-construct large drug-target or DPIs Complex Networks (CNs). For instance, we reconstructed the CN of the US FDA benchmark dataset with 855 nodes 519 drugs+336 targets). We predicted CN with similar topology (observed and predicted values of average distance are equal to 6.7 vs. 6.6). These CNs can be used to explore large DPIs databases in order to discover both new drugs and/or targets. Finally, we illustrated in one theoretic-experimental study the practical use of 2D MI-DRAGON. We reported the prediction, synthesis, and pharmacological assay of 10 different oxoisoaporphines with MAO-A inhibitory activity. The more active compound OXO5 presented IC(50) = 0.00083 muM, notably better than the control drug Clorgyline.
机译:对于不同蛋白质具有高亲和力/非亲和力的药物之间,可能有许多对可能发生的药物-蛋白质相互作用(DPI / nDPI)。这一事实使时间和资源变得昂贵,例如,确定单个药物所有可能的配体-蛋白质相互作用。从这个意义上讲,我们可以使用定量构效关系(QSAR)模型进行合理的DPI预测。不幸的是,几乎所有的QSAR模型都只能预测针对一个目标的活动。为了解决这个问题,我们可以开发多目标QSAR(mt-QSAR)模型。在这项工作中,我们介绍了2D MI-DRAGON技术,它是基于两个不同的知名软件的DPI的新预测器。我们使用软件MARCH-INSIDE(MI)来计算目标的3D结构参数,并使用软件DRAGON来计算2D分子描述符,以显示药物库中存在的所有已知DPI的药物(美国FDA基准数据集)。这两类参数都用作不同人工神经网络(ANN)算法的输入,以寻找准确的非线性mt-QSAR预测器。发现的最佳ANN模型是轮廓为MLP 21:21-31-1:1的多层感知器(MLP)。该MLP正确地对339个DPI中的303个(灵敏度= 89.38%)和510个nDPI中的480个(特异性= 94.12%)进行了正确分类,相当于训练准确率= 92.23%。该模型的验证是通过外部预测序列进行的,灵敏度为92.18%(625/678 DPIs;特异性为90.12%(730/780 nDPIs),准确度为91.06%。2D MI-DRAGON提供了一个很好的机会快速计算一种药物的所有可能DPI,使我们能够重建大型药物靶标或DPI复杂网络(CN),例如,我们重建了855个节点,519种药物和336种靶点的美国FDA基准数据集)。我们用相似的拓扑预测了CN(平均距离的观测值和预测值等于6.7对6.6)。这些CN可用于探索大型DPI数据库,以发现新药和/或靶标。最后,我们在一项理论实验研究中说明了2D MI-DRAGON的实际使用。我们报道了具有MAO-A抑制活性的10种不同的氧代异戊二烯的预测,合成和药理学测定。活性更高的化合物OXO5的IC(50)= 0.00083μM,明显好于对照药物Clorgyline。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号